Physician profile
George Murphy
NPI 1831693795
$6,712.67
in general payments reported to CMS, 2019-2025
25 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $1,764 · 2023: $1,599 · 2024: $1,336 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,229 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,228.92 |
| Education | $147.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,627.53 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Pfizer INC. | $781.71 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $611.15 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $521.32 | 2024-2025 | |
| Amgen INC. | $469.83 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $399.72 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.45 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $315.49 | 2022-2025 | Amvuttra |
| Boston Scientific Corporation | $310.04 | 2022-2025 | Watchman Access System, Watchman Flx, Bodyguardian |
| Cmp Pharma, INC. | $207.07 | 2021-2023 | Tadliq, Norliqva, Carospir |
| Edwards Lifesciences Corporation | $175.81 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $152.21 | 2022-2025 | |
| Genzyme Corporation | $127.78 | 2021-2023 | |
| Glaxosmithkline, LLC. | $116.92 | 2022 | |
| Bridgebio Pharma, INC. | $112.53 | 2025 | Attruby |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $100.83 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $89.18 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $58.90 | 2022-2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $47.70 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $33.36 | 2024-2025 | Inspire |
| Silk Road Medical, INC. | $28.23 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Kowa Pharmaceuticals America, INC. | $28.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.33 | 2023 | Xarelto |
| Medtronic, INC. | $14.14 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.